Results 111 to 120 of about 6,725 (159)

PARP3 Promotes SARS-CoV-2 Replication via Interaction with the Viral Nucleocapsid Protein. [PDF]

Kobe J Med Sci
Adyaksa DNM, Rhamadianti AF, Deng L, Abe T, Matsui C, Shoji I.   +5 more
europepmc   +1 more source

Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers. [PDF]

Mol Carcinog
Bai J, Ji F, Zhao X, Wang H, Huang X, Wei J, Yang Z, Chen S, Zhang W, Zhang P, He X, Liu L, Xu G.   +12 more
europepmc   +1 more source

Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights. [PDF]

Clin Cancer Res
Brodsky AL, Asare A, Fellman B, Anderson K, Yao J, Lee S, Tran H, Xu X, Liu J, Celestino J, Hajek RA, Morgan MB, Mohammad M, Soliman P, Shafer A, Sood AK, Bodurka D, Fleming ND, Onstad Grinsfelder M, Milojevic L, Jazaeri AA, Mills GB, Coleman RL, Westin SN.   +23 more
europepmc   +1 more source

WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers. [PDF]

Oncotarget
El-Deiry WS, Hernando-Calvo A, Dizon D, Magidi S, Bresson C, Cheng L, Liu J, Hu Z, Hattum C, Meissner T, Grisson R, Liu L, Oberoi A, Frankel NZ, Wunder F, Kurzrock R.   +15 more
europepmc   +1 more source

Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance. [PDF]

J Clin Invest
Liu D, Tao K, Xu C, Yang W, Cai C, Feng C, Xiong K, Wu S, Lin Y, Peng Z, Chi J, Pan W, Zhong Q, Liu J, Li X, Liu X, Zhou D, Ma D, Zhao GN, Xia Y, Fang Y, Gao Q.   +21 more
europepmc   +1 more source

Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis. [PDF]

J Mol Med (Berl)
Lin CY, Chao AS, Chao A, Wu RC, Yu AL, Fu CH, Teng YC, Huang RY, Lai CH.   +8 more
europepmc   +1 more source

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. [PDF]

RSC Adv
Rani D, Plebanski M, Chatterjee T.
europepmc   +1 more source

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cancers (Basel)
Gąsowska-Bodnar A, Gąsowska-Bajger B, Żołnierek A, Żołnierek J, Bodnar L.   +4 more
europepmc   +1 more source

Young Investigator Award 2026: Extent and incidence of pseudo-worsening of kidney function due to oral antitumor therapeutics in the AMBORA cohort: an analysis of real-world data. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Sponfeldner MI.
europepmc   +1 more source